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Abstract
Background: To determine the effect of riociguat, an oral, selective soluble guanylate cyclase stimulator, on the net
digital ulcer (DU) burden in systemic sclerosis (SSc).
Methods: Participants with SSc-related active or painful indeterminate DUs were recruited in a multicenter, double-
blind, randomized, placebo-controlled, proof-of-concept trial. Eligible participants were required to have at least
one visible, active ischemic DU or painful indeterminate DU at screening, located at or distal to the proximal
interphalangeal joint and that developed or worsened within 8 weeks prior to screening. Participants were
randomized 1:1 to placebo or riociguat in individualized doses (maximum of 2.5 mg three times daily) during an 8-week
titration period, followed by an 8-week stable dosing period. This was followed by an optional 16-week open-label
extension phase for participants with active DU/reoccurrence of DUs within 1month of the end of the main treatment
phase. The primary endpoint was the change from baseline to week 16 in net ulcer burden (NUB), analyzed using
ANCOVA. Other endpoints included plasma biomarkers and proportion of participants with treatment-emergent adverse
events (AEs).
Results: Seventeen participants (eight placebo, nine riociguat) were randomized at five centers. Six participants in each
group transitioned to the open-label extension. Baseline characteristics were comparable between the treatment groups,
except participants randomized to placebo were older and had longer disease duration (p < 0.05). At baseline, the mean
(SD) NUB was 2.5 (2.0) in the placebo and 2.4 (1.4) in the riociguat. No significant treatment difference was observed in
the change from baseline to 16 weeks in NUB (adjusted mean treatment difference − 0.24, 95% CI (− 1.46, 0.99), p = 0.70).
Four participants experienced five serious AE (four in riociguat and one in placebo); none was considered related to study
medication. Statistically significant elevation of cGMP was observed at 16 weeks in the riociguat group (p = 0.05); no other
biomarkers showed significant changes. In the open-label extension, participants in the riociguat-riociguat arm had
complete healing of their DUs.
Conclusion: In participants with SSc-DU, treatment with riociguat did not reduce the number of DU net burden
compared with placebo at 16 weeks. Open-label extension suggests that longer duration is needed to promote DU
healing, which needs to be confirmed in a new trial.
Trial registration: ClinicalTrials.gov, NCT02915835. Registered on September 27, 2016.
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Background
Systemic sclerosis (SSc) is an autoimmune disorder featur-
ing chronic, fibrosing, autoimmune responses characterized
by small vessel vasculopathy, autoantibody production, and
fibroblast dysfunction leading to increased deposition of
extracellular matrix [1]. Raynaud’s phenomenon (RP) is an
almost universal manifestation of SSc, with 95% of all
patients being affected, resulting in digital ulcers (DUs) in
approximately 30% of the patients each year. DUs are asso-
ciated with substantial morbidity (reduced quality of life,
pain, disability, and disfigurement) that can escalate to
gangrene and amputation in approximately 15% of patients
[2, 3]. There are no drugs approved in the USA for the
treatment of DUs. Treatments that have shown potential
include calcium channel blockers, prostacyclin analogs, and
endothelin receptor antagonists. Bosentan, a dual endothe-
lin receptor antagonist, is approved in Europe to reduce the
number of new DUs in patients with SSc. Trials and case
series show beneficial efficacy of phosphodiesterase 5
(PDE5) inhibitors in healing of SSc-DUs, and this finding is
supported by a meta-analysis [4].
Riociguat is the first in class of a new group of com-
pounds, soluble guanylate cyclase (sGC) stimulators.
Riociguat directly stimulates sGC, thereby increasing the
levels of the signaling molecule cGMP. The cGMP mol-
ecule plays a pivotal role in regulating cellular processes,
such as vascular tone, proliferation, fibrosis, and inflam-
mation. Riociguat has a dual mode of action, directly
stimulating sGC independent of nitric oxide (NO) and in-
creasing the sensitivity of sGC to NO [5, 6]. Riociguat is
approved for the treatment of two forms of pulmonary
hypertension, pulmonary arterial hypertension (PAH), and
chronic thromboembolic pulmonary hypertension [7–9].
In pre-clinical studies, riociguat has been shown to have
vasodilatory, anti-proliferative, vascular remodeling, anti-
fibrotic, and anti-inflammatory properties [10–15]. A re-
cent single-dose, crossover trial showed that riociguat was
well tolerated in patients with RP and resulted in im-
proved digital blood flow in some patient subsets, with
high inter-individual variability [16]. In an exploratory
analysis of a phase 2 trial of riociguat in patients with early
diffuse cutaneous SSc, there was a numerical tendency to-
ward a reduction of RP symptoms and attack frequency
with riociguat treatment compared with placebo [17].
The present proof-of-concept trial was designed to as-
sess the efficacy and safety of 16 weeks of treatment with
riociguat in a randomized, placebo-controlled clinical
trial in patients with SSc-associated DUs followed by an
optional open-label extension for additional 16 weeks.
Methods
Study design
This was an investigator-initiated, multicenter, double-
blind, randomized, placebo-controlled, parallel group,
proof-of-concept study comprising a 16-week treatment
period (8-week titration, 8-week maintenance) followed by
16-week open-label extension phase for participants with
active digital ulcer or reoccurrence of DUs within 1month
of the end of the main treatment phase (ClinicalTrials.gov
Identifier: NCT02915835). Participants without an ischemic
active or painful indeterminate DU after completion of the
treatment period had a safety follow-up visit 4-weeks post-
treatment. The study was conducted at five scleroderma
centers in the USA. The Sponsor (Dinesh Khanna, MD)
received an IND exemption from the Food and Drug Ad-
ministration. Each site’s institutional review board or ethics
committee approved the protocol before the study com-
menced. The study was conducted in accordance with the
principles of the Declaration of Helsinki. After providing
written informed consent, participants entered a screening
phase (lasting up to 2 weeks), where their eligibility was
evaluated (Fig. 1). Participants completed a diary detailing
the number and duration of Raynaud’s attacks per day for a
period of at least seven consecutive days before the baseline
visit.
Randomization and masking
Eligible participants were randomized in a 1:1 ratio to
either riociguat or matching placebo (provided by the
Bayer). The Data Coordinating Center (DCC) at the
University of Michigan prepared the randomization
schedule, using permuted block randomization with size
2 for the first block and then the random block sizes of
2 and 4 thereafter (block sizes were known only by the
DCC). A secure web-based randomization and drug dis-
pensing application were built by the DCC that was used
by coordinators to obtain the randomization number
and medication bottle numbers. This information was
printed for the subject binder and used to prepare an in-
vestigator-signed prescription for the site pharmacist.
The study staff (including the research pharmacists and
assessors of DU) and participants were blinded to the
treatment assigned.
In the titration phase of 8 weeks, participants started
at a dose of 1.0 mg three times a day (TID). The individ-
ual study medication dose for the next titration step was
determined every 2 weeks according to the patient’s
well-being and the peripheral systolic blood pressure
measured at trough before intake of the morning dose
according to the individual dose titration scheme (Fig. 2).
The dose was increased by 0.5 mg increments no sooner
than 2 weeks (± 4 days) apart to 1.5 mg, 2 mg, and 2.5 mg
TID, resulting in a potential maximum total daily dose
of 7.5 mg (2.5 mg TID). Participants were maintained on
a lower dose if higher doses were not tolerated (mini-
mum dosage of 0.5 mg TID, total daily dose 1.5 mg).
While it was possible for a participant to be up-titrated
and then down-titrated during this phase, once a
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participant had been down-titrated, they remained at
that dose, and dose escalation was not implemented
again. The established individual dose was then taken as
the “optimal individual dose” to be administered for the
remaining duration of study. To maintain the blinding
of the treatment arms, participants randomized to the
placebo group underwent sham titration from visit 1 on-
wards during the dose-titration period.
At week 16, all participants who agreed to continue in
the open-label extension were assigned to treatment
with riociguat. During the first 8 weeks of the open-label
extension phase, participants previously on placebo were
Fig. 1 Consort diagram
Fig. 2 Study design
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up-titrated on riociguat as per the individual titration al-
gorithm described in the double-blind treatment phase.
Participants randomized to riociguat in the double-blind
study treatment phase also underwent a titration phase
in the open-label extension.
Patient selection
Eligible patients were ≥ 18 years old with a diagnosis of
SSc according to the American College of Rheumatology
(ACR)/European League Against Rheumatism (EULAR)
2013 classification criteria (total score of ≥ 9) [18]. Par-
ticipants were required to have at least one visible, active
ischemic DU or painful indeterminate DU at screening,
located at or distal to the proximal interphalangeal joint,
and that developed or worsened within 8 weeks prior to
screening. An active DU was defined as a full-thickness
skin lesion, > 3 mm in maximal diameter, with loss of
epithelization, epidermis, and dermis. An indeterminate
ulcer was defined as one where denudation could not be
visualized and there were no other clinical features of
activity. We excluded DUs due to calcinosis (based on
baseline hand X-ray in every participant), paronychia,
and osteomyelitis. We also excluded fissures, pitting
scars, hyperkeratotic lesions, and DUs over the metacar-
pophalangeal joints (MCPs) or elbows. Photographs of
the cardinal DU were taken and confirmed to meet the
study inclusion after the review of the photograph by
DK. We provided a written standardized wound care for
each participant. Females of reproductive potential
(FRP) were required to have a negative urine pregnancy
test. During treatment, FRP were required to obtain
monthly urine pregnancy tests during treatment and
1 month after treatment discontinuation. Oral corticoste-
roids (≤ 10mg/day of prednisone or equivalent), non-ster-
oidal anti-inflammatory drugs, angiotensin receptor
blockers, angiotensin-converting enzyme inhibitors, and
calcium channel blockers were permitted if the participant
was on a stable dose for ≥ 2weeks prior to and including
the baseline visit. Participants with sitting systolic blood
pressure < 95mmHg, sitting heart rate < 50 beats/min, left
ventricular ejection fraction < 40%, or anemia with
hemoglobin < 9.0 g/dl, PAH requiring pharmacologic ther-
apy, significant pulmonary disease [FVC ≤ 50% of predicted,
or DLCO (uncorrected for hemoglobin) ≤ 40% of predicted
done as part of clinical care], active state of hemoptysis or
pulmonary hemorrhage, or any history of bronchial artery
embolization or massive hemoptysis within 3months prior
to screening were excluded in the trial. We excluded partic-
ipants with concomitant use of nitrates or NO donors (such
as amyl nitrate) in any form, PDE5 inhibitors (such as
sildenafil, tadalafil, or vardenafil due to the risk of
hypotension and both target the nitric oxide pathway), and
endothelin receptor antagonists. If the participant was
on PDE5 inhibitors, a wash out of 3 days was required
for sildenafil and 7 days for tadalafil or vardenafil
prior to the baseline visit. Patients who were actively
smoking at the time of consent were excluded due to
the impact of nicotine on pharmacokinetics of rioci-
guat; a quit date of 2 weeks prior to screening was
acceptable. Complete inclusion/exclusion criteria are
provided in Additional file 1.
Study outcome measures
The primary efficacy endpoint was the change from
baseline to week 16 (end of study treatment phase) in
net ulcer burden (NUB). NUB is defined as the total
number of active and painful indeterminate DUs at an
assessment, and the change from baseline in NUB re-
flects both new DUs as well as healed DUs. For example,
if a participant had two active DUs and one painful inde-
terminate DU at baseline (NUB = 3) and at week 4 had
one of the active DUs healed, no change in the other
DUs, and development of a two new active DUs (NUB =
4), the change would be one. NUB captures the overall
impact of DUs on hand function and quality of life and
has been used in a previous trial [2]. Other pre-specified
secondary efficacy endpoints included the proportion
of participants with the following at week 16: healing
of the cardinal DU (healing was defined by re-epithe-
lialization with loss of pain and exudate); healing of
all baseline DUs; no DUs; development of new active
and indeterminate DUs; development or healing of ul-
cers over DIP, PIP, MCPs, and elbows; time to heal-
ing of the cardinal DU and all baseline DUs;
development of new (active or indeterminate) DUs;
improvement of RP based on Raynaud’s Condition
Score (RCS); number and duration of Raynaud’s at-
tacks per day; patient and physician assessment of RP;
symptoms during RP attack (pain, numbness, and tin-
gling); patient’s and physician’s global assessment on
a Likert scale; health-related quality of life as mea-
sured using Patient-Reported Outcomes Measurement
Information System (PROMIS)-29; physical function
[as assessed by Health Assessment Questionnaire
Disability Index (HAQ-DI); and Hand Disability in
Systemic Sclerosis-DU (HDISS-DU)]; visual analog
scales from Scleroderma Health Assessment Question-
naire (SHAQ) assessing burden of digital ulcers, Ray-
naud’s disease, gastrointestinal involvement, breathing,
and overall disease; and documentation of digital is-
chemia requiring intravenous prostacyclin or digital
gangrene or amputation.
Biomarker measurement
To examine the effect of riociguat on biomarkers, patient
plasma was collected at baseline and week 16. Plasma
from age- and sex-matched healthy controls was also
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obtained. The biomarkers were measured by enzyme-
linked immunosorbent assays (ELISA) and included total
vascular endothelial growth factor (VEGF, R&D Systems),
tissue plasminogen activator (tPA, Abcam), soluble E-
selectin (sE-selectin, R&D Systems), basic fibroblast
growth factor (bFGF, R&D Systems), vascular cell adhe-
sion molecule 1 (VCAM-1, RayBiotech), soluble intracel-
lular adhesion molecule 1 (sICAM-1, RayBiotech), N-
terminal propeptide of type I collagen (PINP, MyBio-
Source), matrix metalloproteinase 12 (MMP12, RayBio-
tech), CXCL4 (R&D Systems), cyclic guanylyl cyclase
(cGMP, Cayman Chemical), endostatin (R&D Systems),
and soluble fms-like tyrosine kinase 1 (sFLT1, R&D
Systems).
Sample size
The planned sample size of 20 participants was based
primarily on practical considerations, not on power to
achieve a pre-determined treatment difference. The goal
of this pilot study was to obtain preliminary estimates of
the magnitude of treatment effects of key efficacy and
safety parameters. There are no published data on the
minimal clinically important difference (MCID) for the
change from baseline in NUB at week 16 (our primary
efficacy endpoint), and our study did not seek to estab-
lish the MCID. Rather, we designed this pilot study with
a placebo control arm and randomization to reduce bias
in the estimation of NUB, so that we could also obtain a
preliminary estimate of treatment differences. As ex-
pected with a pilot study, only large treatment differ-
ences can be detected. With the proposed sample of 10
riociguat and 10 placebo participants, we calculated the
effect size (mean treatment difference divided by stand-
ard deviation) for the primary efficacy endpoint to be
1.253 with 80% power and a two-sided type I error of
5% based on a two-sample t test. If a statistically signifi-
cant would be observed in our small study, it would
need to be replicated in a larger confirmatory study.
Statistical analysis
Continuous variables were summarized using means,
standard deviations (SD), median, interquartile range
(IQR), and range, and qualitative variables were summa-
rized using counts and percentages. Mean (SD) is
reported, unless otherwise noted. The primary and
secondary efficacy endpoints were analyzed using the
modified intention-to-treat population (MITT), defined
as all participants randomized, receiving at least one
dose of treatment, and having at least one post-baseline
efficacy assessment. As a sensitivity analysis, the primary
endpoint was also analyzed using the per-protocol set,
defined as the MITT population who did not have a
major protocol violation. For the primary analysis,
changes in NUB were compared in the two treatment
groups using an ANCOVA model, with terms for treat-
ment group and baseline NUB value. Distributional
assumptions were assessed. Analysis for secondary out-
come measures that are continuous was performed using
a similar approach as that for the primary endpoint. For
analyses of discrete secondary outcomes measures, we
used Fisher’s exact tests. Poisson regression was used for
outcome measures that were counts (e.g., number of AEs)
and log-rank tests, and Kaplan-Meier plots were used for
time-to-event outcomes. Plasma biomarker changes from
baseline (week 0) to week 16 were analyzed using the
ANCOVA model. Safety analyses were performed on the
safety analysis set which included all participants who
were randomized and received at least one dose of the
study drug. Statistical tests were conducted at the 0.05 sig-
nificance level (with no adjustments for multiplicity) using
two-tailed tests. Statistical analyses were performed using
SAS version 9 or higher. Further details on the statistical
analysis can be found in Additional file 2.
Results
Participant disposition and baseline characteristics
Twenty-five participants were screened across 5 centers
in the USA between January 2017 and May 2018. Seven-
teen participants were randomized to either placebo
(n = 8) or riociguat (n = 9), of which all 17 (88%) partici-
pants formed the MITT and safety analysis sets (Fig. 2),
and the trial was stopped in May 2018 due to warm
weather and poor recruitment and since this was a
proof-of-concept study. Fifteen participants were in-
cluded in the per-protocol analysis set (8 in placebo and
7 in riociguat). One participant withdrew in each group.
One riociguat participant was withdrawn by the investi-
gator due to worsening DU and RP, and the placebo
participant completed treatment but did not return for
the safety follow-up at week 20. Mean compliance with
study drug in the treatment phase was 92%, 96% with
placebo, and 88% with riociguat. Six subjects in each
group progressed to the open-label extension phase with
a 100% compliance till the end of the phase.
Baseline demographics and clinical characteristics were
largely similar between the two groups, but the partici-
pants in the placebo group had longer duration (in
years) of SSc diagnosis (mean [SD] 15.0 [8.2] years vs 6.2
[5.8] years) and of non-Raynaud’s symptoms (17.5 [11.2]
years vs 7.1 [6.0] years). (Table 1). At baseline, the mean
[SD] NUB was 2.5 (2.0) in the placebo group and 2.4
(1.4) in the riociguat group. Participants randomized to
riociguat had numerically worse RP—higher RCS, more
frequent and longer Raynaud’s attacks, more intense
symptoms associated with RP (pain, numbness, and tin-
gling), and higher S-HAQ scores for DUs indicating in-
creased interferences of DUs with daily activities.
Nagaraja et al. Arthritis Research & Therapy          (2019) 21:202 Page 5 of 14
Table 1 Baseline demographic and clinical characteristics of all of the randomized patients













Age in years, mean (SD) 61 (17) 43 (14) 51 (18) 61 (20) 44 (14) 52 (19)
Gender, n (%)
Male 3 (38) 1 (11) 4 (24) 3 (50) 0 (0) 3 (25)
Female 5 (63) 8 (89) 13 (76) 3 (50) 6 (100) 9 (75)
Race, n (%)
Caucasian 7 (88) 6 (67) 13 (76) 5 (83) 5 (83) 10 (83)
African-American 1 (13) 2 (22) 3 (18) 1 (17) 0 (0) 1 (8)
Others 0 (0) 1 (11) 1 (6) 0 (0) 1 (17) 1 (8)
SSc subset, n (%)
Limited cutaneous SSc 4 (50) 5 (56) 9 (53) 2 (33) 4 (67) 6 (50)
Diffuse cutaneous SSc 4 (50) 4 (44) 8 (47) 4 (67) 2 (33) 6 (50)
Time since SSc diagnosis, in years,
mean (SD)†
15.0 (8.2) 6.2 (5.8) 10.4 (8.2) 14.3 (8.0) 5.2 (6.0) 9.7 (8.2)
Time since first non-RP symptom,
in years, mean (SD)††
17.5 (11.2) 7.1 (6.0) 12 (10.1) 16.9 (12.1) 5.7 (5.8) 11.3 (10.8)
Time since first RP symptom, in
years, mean (SD)††
14.5 (7.9) 7.5 (6.6) 11 (7.9) 13.2 (6.7) 6.9 (6.9) 10.1 (7.3)
Time since first DU,, in years† 8.0 (6.8) 5.4 (4.6) 6.7 (5.7) 9.8 (7.0) 3.5 (3.1) 6.7 (6.1)
Number of DU, mean (SD)†† 2.5 (1.7) 2.7 (1.8) 2.6 (1.7) 2.7 (1.8) 1.7 (0.8) 2.2 (1.5)
Number of active DU 1.4 (1.1) 1.1 (1.0) 1.2 (1.0) 1.2 (1.0) 0.5 (0.5) 0.8 (0.8)
Number of indeterminate DU 1.1 (1.4) 1.6 (1.3) 1.3 (1.3) 1.5 (1.4) 1.2 (1.2) 1.3 (1.2)
Net ulcer burden 2.5 (2.0) 2.4 (1.4) 2.5 (1.7) 2.7 (2.3) 1.7 (0.8) 2.2 (1.7)
Characteristics of Raynaud’s attacks
Raynaud’s Condition Score (0–10
Likert scale), mean (SD)†
3.4 (2.2) 5.4 (1.6) 4.5 (2.1) 4.0 (1.8) 5.1 (1.9) 4.6 (1.8)
Number of Raynaud’s attacks per
day, mean (SD)†
2.2 (1.7) 4.3 (1.7) 3.3 (2.0) 2.4 (1.8) 3.6 (1.4) 3.0 (1.7)
Pain during a RP attack (0–100
VAS scale), mean (SD)†
37.2 (24.6) 54.9 (13.1) 46.6 (20.7) 41.7 (23.6) 53.4 (14.2) 47.5 (19.5)
Numbness during a RP attack
(0–100 VAS scale), mean (SD)†
32.0 (30.2) 40.5 (15.9) 36.5 (23.2) 35.6 (31.4) 43.7 (16.3) 39.7 (24.2)
Tingling during a RP attack
(0–100 VAS scale), mean (SD)†
26.9 (16.1) 34.8 (16.6) 31.1 (16.3) 29.7 (15.7) 37.7 (15.9) 33.7 (15.6)
Duration of RP attacks, in minutes,
mean (SD)†
47.9 (51.6) 101.4 (117.3) 76.4 (93.8) 55.0 (52.6) 112.5 (136.4) 83.7 (103.0)
Patient assessment of RP (0–10
Likert scale)
Severity of RP, mean (SD)† 4.2 (2.7) 7.1 (1.4) 5.8 (2.5) 4.8 (2.5) 7.0 (1.7) 5.9 (2.3)
Severity of DU, mean (SD)† 6.7 (1.9) 8.0 (1.5) 7.4 (1.8) 6.3 (1.6) 8.3 (1.2) 7.3 (1.7)
SHAQ: DUs interfere with daily
activities in past week (theoretical
range, 0–150), median (IQR)
55 (36–102) 116 (98–125) 98 (62–124) 64.3 (33.8) 107.2 (21.3) 85.7 (35.0)
Physician assessment of RP (0–10
Likert scale)
Severity of RP, mean (SD)† 5.4 (3.0) 6.1 (1.0) 5.8 (2.1) 6.2 (2.2) 6.0 (1.3) 6.1 (1.7)
Severity of DU, mean (SD)† 6.3 (2.6) 6.4 (1.9) 6.4 (2.1) 5.6 (2.5) 6.7 (2.5) 6.2 (2.3)
SSc-related antibodies, n (%)‡
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Dosing and exposure
The median duration of exposure to study drug was 112
days in each treatment group. At the end of the 8-week
titration phase, all eight participants in the placebo
group reached the 2.5 mg TID dosing level whereas in
the riociguat group, three reached 1.5 mg TID, one
reached 2.0 mg TID, and four reached the 2.5 mg TID
dosing levels.
Primary efficacy endpoint
There was no statistically significant difference between
riociguat and placebo in the change in NUB (Fig. 3). The
least square (LS) mean change from baseline to 16 weeks
in NUB was − 1.22 in the riociguat group and − 0.98 in
the placebo group (negative score denotes improvement,
treatment difference − 0.24, 95% CI − 1.46 to 0.99; p =
0.70; Table 2). Sensitivity analyses (using the per-proto-
col analysis set or controlling for age in the MITT ana-
lysis set) also showed statistically non-significant
treatment differences (LS mean treatment difference −
0.08, 95% CI − 1.62 to 1.46; p = 0.92 in ANCOVA adjust-
ing for baseline NUB and age).
Secondary endpoints
There were no statistically significant treatment differ-
ences in secondary efficacy endpoints, except for the
eating component of HAQ-DI (Table 2). There were no
statistically significant differences between the two treat-
ments in RCS or frequency of RP attacks, patient self-as-
sessments, PROMIS-29 measures, and overall HAQ-DI
score. However, we noted greater numerical improve-
ments in riociguat, relative to placebo, in some outcome
measures but were not significant (Table 2). Participants
in the riociguat group reported decreased pain due to RP
(LS mean treatment difference 6.71, 95% CI − 14.01 to
27.43; p = 0.49) and tingling due to RP (LS mean treatment
difference 8.67, 95% CI − 13.75 to 31.09; p = 0.41) during
RP attacks and decreased duration of RP attacks (LS mean
treatment difference − 195.1min, 95% CI − 683.7 to 293.5;
p = 0.40) compared to the placebo group (both pain and
tingling due to RP are measured on a 0–100 scale). In both
treatment groups, three (38%) participants underwent heal-
ing of all baseline DUs by week 16, with a median time to
healing of 16 weeks (placebo, 1.15 riociguat; p = 0.35). Heal-
ing of the cardinal DU by week 16 was seen in 6 (75%)
placebo and four (50%) riociguat participants. The median
time to healing of the cardinal DU was 16.0 weeks (IQR
0.14) in the placebo group and 16.6 weeks (IQR 1.15) in the
riociguat group (p = 0.56). The percentage of participants
without any DUs at the end of the study period was two
(25%) in each of the treatment groups. Four (50%) and
three (38%) of placebo and riociguat participants, respect-
ively, developed new ulcers of the 16weeks of treatment
(p = 1.0).
Biomarker data
There were statistical differences in the baseline values
for the biomarkers between healthy controls and all
patients for cGMP, sE-selection, and sICAM1 (p < 0.05,
Additional file 3). No statistical differences were ob-
served in patients in the placebo and riociguat arms at
baseline except for MMP12; patients in the riociguat
group had significantly higher MMP12 levels compared
to the placebo group (p < 0.05, Additional file 3). Our
ANCOVA analysis revealed that after 16 weeks of rioci-
guat treatment, there were no significant changes in the
biomarkers measured, except for cGMP, which was sig-
nificantly elevated in the riociguat group, confirming
target engagement (p = 0.046, Table 3).
Table 1 Baseline demographic and clinical characteristics of all of the randomized patients (Continued)













Anti-centromere B 3 (38) 3 (33) 6 (35) 2 (33) 3 (50) 5 (42)
Anti-topoisomerase I 3 (38) 2 (22) 5 (29) 3 (50) 0 (0) 3 (25)
Anti-RNA polymerase III 0 (0) 1 (11) 1 (6) 0 (0) 1 (17) 1 (8)
Not done 2 (25) 3 (33) 5 (29) 1 (17) 2 (33) 3 (25)
Baseline use of medications, n (%)
Vasodilators 1 (13) 1 (11) 2 (12) 0 (0) 1 (17) 1 (8)
Prednisone 1 (13) 0 (0) 1 (6) 1 (17) 0 (0) 1 (8)
Immunosuppressive 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Mean (SD), unless otherwise mentioned
SSc systemic sclerosis, DU digital ulcer, RP Raynaud’s phenomenon, SHAQ Scleroderma Health Assessment Questionnaire, IQR interquartile range, PAH pulmonary
arterial hypertension, ILD interstitial lung disease, CCB calcium channel blocker
†Calculated from date of screening or at the screening
‡Classes not mutually exclusive
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Safety and tolerability
Four serious AEs (SAEs) in 3 (14%) riociguat partici-
pants were reported: non-Hodgkin lymphoma, non-ST
elevation myocardial infarction, digital ischemia, and
worsening digital ulcer that required hospitalization for
intravenous prostacyclin. One (8%) placebo participant
experienced an SAE: persistent digital ischemia in a toe
that required hospitalization for intravenous prostacyc-
lin. All SAEs were considered not related to the study
treatment. There were no deaths during the study. Thir-
teen adverse events (AEs) were reported in 8 (100%) par-
ticipants in the placebo group and 21 were reported in 9
(100%) participants in the riociguat group (Table 4).
Most AEs were reported as mild or moderate according to
the Common Terminology Criteria for Adverse Events 5.0
(CTCAE 5.0) severity grading system: 13 (100%) in the
placebo group and 77% in the riociguat group. There was
no osteomyelitis or AEs of special interest (clinically sig-
nificant hypotension or hemoptysis).
Open-label extension
There was an improvement in the NUB in both placebo-
riociguat and riociguat-riociguat groups from baseline
and from week 16 of the treatment phase (Fig. 3). In the
riociguat-riociguat group, all the DUs healed by week 16
of the open-label extension. Numerical improvements
were noted in almost all the secondary efficacy end-
points by week 16 of the open-label extension in both
groups but numerically favor in the riociguat-riociguat
group (Table 5). Six SAEs were reported in total. In the
placebo-riociguat arm, SAEs included the following: acute
ileus (participant #1), omental adhesion of lower abdo-
men, transient ischemic attack, aspiration pneumonia, and
deep vein thrombosis (all in participant #2), and acute re-
spiratory failure secondary to pneumonia (participant #3).
In the riociguat-riociguat arm, SAEs included the follow-
ing: pulmonary embolism and acute right rib fractures
with hemopneumothorax (both in participant #1). All
SAEs were considered not related to the study treatment.
There were no deaths during the open-label extension
phase study. Thirty-five AEs were reported in 6 (100%)
participants in the placebo-riociguat group and 19 were
reported in 5 (83%) participants in the riociguat-riociguat
group (Table 4). Most AEs were reported as mild or mod-
erate according to the CTCAE 5.0 severity grading system.
Discussion
The proof-of-concept trial was designed to evaluate the
effect of riociguat on NUB in patients with SSc-related
DUs. We did not find any statistical or clinically mean-
ingful differences in the NUB and other secondary
outcome measures, but we showed target engagement,
as exemplified by an increase in plasma cGMP in the
riociguat group. With a longer duration of treatment
with riociguat, complete healing of DUs was observed as
noted in the open-label extension phase. The safety
profile of riociguat was consistent with that observed
previously in studies of patients with PAH, with no new
safety events identified [9].
Fig. 3 Mean trend over time: change in net ulcer burden. Digital ulcer net burden is defined as the total number of “active” and indeterminate
digital ulcers at an assessment. LS, least squares; SE, standard error; CI, confidence interval. Estimates are from an ANCOVA model with terms for
the treatment group and baseline digital net ulcer burden. Modified intent-to-treat population is defined as all participants randomized, receiving
at least one dose of treatment, and having at least one post-baseline efficacy assessment
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Table 2 Changes from baseline to week 16 in primary and secondary efficacy endpoints
Placebo (N = 8) Riociguat (N = 7) Treatment difference (95% CI) p value
Net ulcer burden, LS mean†* − 0.98 − 1.22 − 0.24 (− 1.46 to 0.99) 0.706
Patient global assessment
for overall disease, LS mean†
− 1.19 0.31 1.50 (− 1.30 to 4.30) 0.27
Patient assessment, LS mean†
Severity of RP − 1.41 − 3.47 − 2.06 (− 4.63 to 0.51) 0.11
Severity of DU − 4.00 − 4.63 − 0.63 (− 3.68 to 2.41) 0.66
Pain during RP attack (0–100) − 7.01 − 0.30 6.71 (− 14.01 to 27.43) 0.49
Numbness during RP attack
(0–100)
− 15.44 − 19.73 − 4.28 (− 33.44 to 24.87) 0.75
Tingling during RP attack
(0–100)
− 7.49 1.18 8.67 (− 13.75 to 31.09) 0.41
Raynaud’s Condition Score,
LS mean†
− 0.82 − 1.15 − 0.33 (− 2.60 to 1.94) 0.76
Number of Raynaud’s attacks
per day, LS mean†
− 0.96 − 1.24 − 0.28 (− 1.36 to 0.79) 0.57
Duration of Raynaud’s attacks
(minutes), LS mean†
150.3 − 44.8 − 195.1 (− 683.7 to 293.5) 0.40
Physician global assessment
for overall disease, LS mean†
− 0.66 − 1.17 − 0.51 (− 2.27 to 1.25) 0.54
Physician assessment of the
severity of RP, LS mean†
− 1.86 − 3.00 − 1.15 (− 3.51 to 1.22) 0.32
Physician assessment of
severity of DU, LS mean†
− 3.81 − 3.54 0.27 (− 2.55 to 3.10) 0.84
SHAQ-DI (VAS range 0–150),
LS mean†
VAS overall disease − 35.74 − 50.35 − 14.60 (− 45.48 to 16.27) 0.32
VAS burden of DU − 53.47 − 43.09 10.38 (− 58.03 to 78.79) 0.75
VAS Raynaud’s − 25.40 − 23.78 1.62 (− 54.56 to 57.80) 0.95
VAS GI − 7.39 16.72 24.11 (− 25.22 to 73.44) 0.31
VAS breathing − 12.69 8.35 21.04 (− 8.05 to 50.13) 0.14
PROMIS-29, LS mean†
Anxiety − 1.50 −3.11 − 1.60 (− 9.77 to 6.56) 0.68
Depression − 0.25 − 3.35 − 3.10 (− 8.65 to 2.45) 0.25
Fatigue 0.46 0.64 0.19 (− 6.26 to 6.63) 0.95
Physical function − 2.24 − 2.46 − 0.22 (− 3.96 to 3.53) 0.90
Sleep disturbance 0.94 − 0.47 − 1.41 (− 4.76 to 1.95) 0.38
Pain interference − 3.06 − 3.69 − 0.62 (− 6.54 to 5.30) 0.82
Pain intensity − 1.63 − 2.74 − 1.11 (− 3.59 to 1.37) 0.35
Ability to participate in
social activities
− 0.46 − 1.68 − 1.22 (− 4.80 to 2.36) 0.47
HAQ-DI, LS mean†
Overall − 0.06 − 0.01 0.04 (− 0.44 to 0.53) 0.84
Dressing and grooming 0.05 − 0.16 − 0.21 (− 0.96 to 0.54) 0.55
Hygiene − 0.27 − 0.39 − 0.11 (− 1.00 to 0.78) 0.79
Arising 0.02 0.36 0.34 (− 0.41 to 1.09) 0.34
Reach 0.01 0.37 0.36 (− 0.46 to 1.19) 0.36
Eating 0.03 − 0.53 − 0.56 (− 1.08 to − 0.03) 0.04
Grip − 0.18 0.16 0.34 (− 0.37 to 1.04) 0.31
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Few therapies are available for DUs in patients with
SSc. In the recently published EULAR guidelines, intra-
venous iloprost and oral sildenafil are recommended for
the treatment of SSc-related DU, and oral bosentan is
recommended for the prevention of new DUs, especially
in patients with multiple digital ulcers despite the use of
CCBs, PDE5 inhibitors, or iloprost therapy [19]. In the
USA, iloprost is currently unavailable, and neither sil-
denafil nor bosentan is approved by the Food and Drug
Administration for the treatment of DUs. Hence, there
is a clear need for therapeutic agents for the manage-
ment of DUs.
We designed the pilot trial to explore the unmet need
of a therapeutic agent to treat SSc-DU by utilizing the
pleiotropic effect of riociguat on vascular remodeling
and anti-fibrotic, anti-proliferative effect, and anti-in-
flammatory effects [10–15]. We did not find statistically
significant improvements in the primary and secondary
outcome measures, including patient-reported symp-
toms of RP and PROs. There are several reasons for this
negative trial. First, the trial design excluded PDE5 in-
hibitors due to relative contraindication of PDE5
inhibitors and riociguat (both target nitric oxide pathway
and risk of significant hypotension). The trial allowed
background stable CCBs, ACE inhibitors, and anti-plate-
let therapies. PDE5 inhibitors have become the mainstay
for the management of SSc-DU, especially those who do
not respond or are intolerant to CCBs [19]. This likely
led to the recruitment of a population with milder bur-
den of digital disease—the mean number of active and
painful intermediate DUs at baseline was 2.6. Second,
the participants in the trial had longer disease duration
(mean [SD] 12.0 [10.1] years) compared to the recently
completed RISE-SSc trial—a phase 2b randomized con-
trolled trial in participants with early dcSSc (disease dur-
ation of mean 9months) where riociguat was associated
with trends in improvement in RP at 14 weeks and DUs
at 52 weeks [17]. Although the participants in the pla-
cebo group had longer disease duration (15 [8.2] years
vs 6.2 [5.8] years), both groups of patients may have had
chronic irreversible vasculopathy that was not amenable
to oral therapy like riociguat. Third, the duration of rio-
ciguat treatment in the RESCUE study, especially with
an 8-week titration to maximum tolerated dose, may be
suboptimal for healing of DUs. In the open-label exten-
sion phase, all baseline and cardinal ulcers in the rioci-
guat-riociguat arm. This observation is a likely
indication that a longer duration of riociguat treatment
can cause healing of DUs. A similar observation was
demonstrated in a RCT of oral treprostinil where the
primary outcome of change in net DU burden was not
met at week 20 but showed efficacy during the 1-year
open-label extension phase when exposed to oral tre-
prostinil [20]. Also, an increase in DU burden was noted
in the year after oral treprostinil discontinuation despite
adjustment to seasonal variations.
The biomarkers that we chose have been shown to be
associated with SSc vasculopathy [21]. At baseline, there
were statistically significant elevations in plasma cGMP,
sE-selection, and sICAM1 in participants compared to
healthy controls, which coincides with the published lit-
erature [22–24]. After riociguat treatment, none of the
biomarkers measured was significantly altered, except
for cGMP, which is expected, and supports the target
engagement.
Table 3 Plasma biomarker changes from baseline (week 0) to
week 16. Data presented as Mean (SD)
Biomarkers Adjusted Means (SE)a
Placebo (n = 8) Riociguat (n = 9) p-value
cGMP (nM) 41.22 (50.2) 198.5 (47.03) 0.046
CXCL4 (ng/ml) -7.3 (105.9) -190.7 (99.8) 0.23
sE-Selectin (ng/ml) -2.5 (2.0) -4.7 (1.9) 0.45
VEGF (pg/ml) -34.7 (10.1) -29.8 (9.5) 0.73
sFLT1 (pg/ml) -218.0 (211.8) -220.5 (183.2) 0.99
tPA (ng/ml) -0.5 (0.5) -1.2 (0.5) 0.32
bFGF (pg/ml) -0.03 (0.29) 0.20 (0.28) 0.58
sICAM1 (ng/ml) -39.2 (50.2) 70.5 (47.3) 0.14
VCAM1 (ng/ml) -3.4 (11.0) 10.3 (10.4) 0.39
PINP (pg/ml) -6.6 (11.0) 7.1 (10.3) 0.38
MMP12 (ng/ml) 0.12 (0.14) -0.09 (0.13) 0.31
Endostatin (ng/ml) -96.8 (132.2) -299.0 (124.5) 0.29
1biomarker values analyzed on natural scale using ANCOVA, adjusting for
baseline biomarker value
Table 2 Changes from baseline to week 16 in primary and secondary efficacy endpoints (Continued)
Placebo (N = 8) Riociguat (N = 7) Treatment difference (95% CI) p value
Walking − 0.12 0.35 0.47 (− 0.18 to 1.12) 0.14
Common daily activities 0.04 − 0.29 − 0.33 (− 1.17 to 0.51) 0.40
HDISS-DU, LS mean† − 0.32 − 0.47 − 0.14 (− 1.75 to 1.46) 0.85
LS mean least squares mean from an ANCOVA model with treatment and baseline value as covariates, SE standard error, DU digital ulcer, RP Raynaud’s
phenomenon, SHAQ-DI Scleroderma Health Assessment Questionnaire Disability Index, VAS visual analog scale, GI gastrointestinal, PROMIS Patient-Reported
Outcomes Measures Information System, HAQ-DI Health Assessment Questionnaire Disability Index, HDISS-DU Hand Disability in Systemic Sclerosis Digital Ulcer
*DU net burden is defined as the total number of active and painful indeterminate digital ulcers at an assessment; †Estimates and p-values are from an ANCOVA
model, adjusting for baseline values of the outcome
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Table 4 Summary of adverse events
Double-blind phase Open-label extension
PBO (n = 8) RIO (n = 9) PBO-RIO (n = 6) RIO-RIO (n = 6)
Treatment emergent AEs/SAEs 13 21 35 19
Treatment emergent AEs, n (%) 12 (92) 18 (86) 29 (83) 17 (90)
Participants with AEs, n (%) 8 (100) 9 (100) 6 (100) 5 (83)
Treatment emergent SAEs, n (%) 1 (8) 4 (19) 6 (17) 2 (10)
Participants with SAEs, n (%) 1 (13) 3 (33) 3 (50) 1 (17)
Participants with AEs leading to
study drug discontinuation, n (%)
0 (0) 1 (11) 2 (33) 0 (0)
Participants with SAEs leading to
study drug discontinuation, n (%)
0 (0) 0 (0) 1 (17) 0 (0)3
AEs according to system organ
class‡, number of events (%)
Blood and lymphatic system
disorders
0 (0) 3 (14) 1 (3) 0 (0)
Cardiac disorders 1 (8) 2 (10) 3 (9) 2 (11)
Gastrointestinal disorders 1 (8) 2 (10) 9 (26) 4 (21)
General disorders 1 (8) 0 (0) 3 (9) 2 (11)
Hepatobiliary disorders 0 (0) 1 (5) 0 (0) 0 (0)
Infections and infestations 1 (8) 2 (10) 6 (17) 2 (11)
Injury, poisoning, and procedural
complications
1 (8) 0 (0) 0 (0) 0 (0)
Metabolism and nutrition disorders 0 (0) 0 (0) 0 (0) 1 (5)
Musculoskeletal and connective
tissue disorders
1 (8) 3 (14) 1 (3) 4 (21)
Nervous system disorders 4 (31) 5 (24) 3 (9) 0 (0)
Renal and urinary disorders 0 (0) 0 (0) 6 (17) 0 (0)
Respiratory, thoracic and mediastinal
disorders
0 (0) 0 (0) 1 (3) 3 (16)
Surgical and medical procedures 1 (8) 0 (0) 0 (0) 0 (0)
Vascular disorders 2 (15) 3 (14) 1 (3) 1 (5)
SAEs according to system organ class‡,
number of events (%)
Blood and lymphatic system disorders
Lymphoma 0 (0) 1 (33) 0 (0) 0 (0)
Cardiac disorders
NSTEMI 0 (0) 1 (33) 0 (0) 0 (0)
Gastrointestinal disorders
Acute ileus 0 (0) 0 (0) 1 (17) 0 (0)
Omental adhesions of lower abdomen 0 (0) 0 (0) 1 (17) 0 (0)
Infections and infestations
Aspiration pneumonia 0 (0) 0 (0) 1 (17) 0 (0)
Musculoskeletal and connective tissue
disorders
Acute right rib fractures with
hemopneumothorax
0 (0) 0 (0) 0 (0) 1 (17)
Nervous system disorders
Possible transient ischemic attack 0 (0) 0 (0) 1 (17) 0 (0)
Respiratory, thoracic, and mediastinal disorders
Nagaraja et al. Arthritis Research & Therapy          (2019) 21:202 Page 11 of 14
Table 4 Summary of adverse events (Continued)
Double-blind phase Open-label extension
PBO (n = 8) RIO (n = 9) PBO-RIO (n = 6) RIO-RIO (n = 6)
Acute respiratory failure secondary
to pneumonia
0 (0) 0 (0) 1 (17) 0 (0)
Vascular disorders
Digital ischemia 1 (100) 1 (33) 0 (0) 0 (0)
DU 0 (0) 1 (33) 0 (0) 0 (0)
Deep vein thrombosis 0 (0) 0 (0) 1 (17) 0 (0)
Pulmonary embolism 0 (0) 0 (0) 0 (0) 1 (17)
Safety analysis set for the double-blind treatment period. Values are the number (%)
AEs adverse events, SAEs serious adverse events, NSTEMI non-ST elevation myocardial infarction, DU digital ulcer
‡According to the Medical Dictionary for Regulatory Activities, version 18.0
Table 5 Summary of changes in the efficacy measures at the end of open-label extension
Placebo-riociguat (N = 6) Riociguat-riociguat (N = 6)
Baseline* Week 16 OLE Change from baseline Baseline* Week 16 OLE Change from baseline
Net ulcer burden 2.7 (2.2) 1.5 (1.1) − 1.2 (2.3) 1.67 (0.8) 0 (0) − 1.67 (0.8)
Patient global assessment for
overall disease
4.3 (2.2) 3.3 (1.9) − 1.0 (2.3) 4.2 (2.9) 3.5 (1.6) − 0.7 (2.6)
Patient assessment
Severity of RP 4.8 (2.5) 3 (1.9) − 1.8 (2.3) 7.0 (1.7) 3.0 (2.7) − 4.0 (3.3)
Severity of DU 6.3 (1.6) 2.8 (1.5) − 3.5 (2.6) 8.3 (1.2) 1.0 (0.9) − 7.3 (1.9)
Physician global assessment for
overall disease
4.8 (1.8) 5.2 (1.7) 0.6 (2.9) 6 (1.7) 3.2 (1.7) − 1.8 (2.7)
Physician assessment of severity
of RP
6.2 (2.2) 4.7 (2.2) − 1.4 (2.4) 1.3 (5.5) 3.0 (2.2) − 3.0 (1.3)
Physician assessment of severity
of DU
5.6 (2.5) 2.8 (2.1) − 2.2 (2.2) 6.7 (2.2) 0.5 (0.8) − 6.2 (2.1)
SHAQ-DI (VAS range 0–150)
VAS overall disease 94.2 (20.1) 65.5 (24.1) − 28.7 (26.9) 100.5 (24.4) 42.8 (25.8) − 57.7 (32.7)
VAS burden of DU 64.3 (33.8) 39.2 (35.2) − 25.2 (42.1) 107.2 (21.3) 10.0 (6.3) − 97.2 (24.2)
VAS Raynaud’s 56.8 (36.7) 37.8 (39.7) − 19.0 (47.5) 69.7 (38.3) 36.7 (40.2) − 33.0 (46.5)
VAS GI 6.8 (7.5) 46.2 (47.8) 39.3 (47.7) 44.5 (29.9) 45.5 (33.6) 1.0 (28.6)
VAS breathing 18.5 (29.4) 20.5 (27.5) 2.0 (14.7) 40.3 (22.6) 33.7 (27.2) − 6.7 (24.9)
PROMIS-29
Anxiety 51.5 (9.8) 51.9 (9.5) 3.2 (9.4) 61.4 (14.3) 56.7 (9.4) − 4.8 (11.4)
Depression 51.2 (8.8) 51.4 (8.7) 0.2 (4.2) 57.4 (7.1) 55.7 (8.3) − 1.7 (7.8)
Fatigue 44.7 (8.7) 54.0 (3.8) 9.2 (6.4) 57.6 (6.7) 54.7 (7.0) − 2.9 (9.5)
Physical function 35.3 (5.4) 33.8 (3.4) − 1.5 (4.1) 34.7 (3.3) 32.0 (3.6) − 2.7 (1.9)
Sleep disturbance 51.1 (5.1) 49.8 (4.3) − 1.3 (7.9) 52.3 (2.0) 49.9 (1.9) − 2.4 (3.2)
Pain interference 60.3 (3.4) 49.6 (9.0) − 10.6 (8.3) 63.8 (6.1) 58.5 (3.1) − 5.3 (7.5)
Pain intensity 6.5 (1.5) 3.7 (2.1) − 2.8 (3.0) 8.7 (0.8) 5.0 (1.1) − 3.7 (1.0)
Ability to participate in
social activities
41.1 (3.0) 40.7 (5.0) − 0.4 (7.2) 45.7 (7.5) 41.8 (3.6) − 4.0 (5.7)
HAQ-DI 1.3 (0.7) 1.5 (0.5) 0.9 (0.5) 1.2 (0.6) 0.9 (0.5) − 0.3 (0.5)
HDISS-DU 5.2 (1.7) 5.5 (1.8) 0.3 (1.0) 4.8 (2.3) 4.2 (1.9) − 0.7 (2.0)
* Baseline data is at the start of double blind study. DU digital ulcer, RP Raynaud’s phenomenon, SHAQ-DI Scleroderma Health Assessment Questionnaire Disability
Index, VAS visual analog scale, GI gastrointestinal, PROMIS Patient-Reported Outcomes Measures Information System, HAQ-DI Health Assessment Questionnaire
Disability Index, HDISS-DU Hand Disability in Systemic Sclerosis Digital Ulcer
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Strengths and limitations of the study
We included experienced centers with specialized ex-
pertise in the management of SSc-related DUs. The
wound care of the DUs was standardized across the par-
ticipating sites. All DUs were defined, photographed,
and confirmed by the corresponding author, suggesting
a level of standardization in DU assessment. The study
is not without limitations. First, we had a small sample
size as this was a pilot study to obtain preliminary esti-
mates of treatment effects in efficacy and safety. We also
stopped the trial prematurely due to difficulty in recruit-
ment, as majority of current management of DU in the
USA includes PDE5 inhibitors. Second, there was a base-
line imbalance in the study population with the placebo
group having participants with longer disease duration,
but the participants in the riociguat group had more se-
vere self-reported disease in terms of RP and DU.
Conclusions
In conclusion, treatment with riociguat in this trial did
not reduce the NUB in patients with SSc. The negative
results may reflect lack of power, low NUB at baseline,
moderate-to-severe vasculopathy with long-term disease,
shorter duration of the trial, and difficulty to recruit pa-
tients in the era of widespread use of PDE5 inhibitors.
This and other recent trials also highlight the changing
epidemiology of SSc-DU due to the availability of some-
what effective pharmacologic therapies such as PDE5
inhibitors, prostacyclin analogs, and better wound care
management of these ulcers [20, 25, 26]. Future trials
should acknowledge this during the trial design and plan
longer trials with background standard of care treat-
ments. There was a trend toward DU healing with
longer duration of treatment with riociguat in the open-
label extension, but this observation will need to be
confirmed in a larger RCT.
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